An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction.

Advances in Therapy
Dana Drzayich AntolPatricia A Russo

Abstract

Sacubitril/valsartan has been established as an effective treatment for heart failure (HF) with reduced ejection fraction based on clinical trial data; however, little is known about its use or impact in real-world practice. This study included data from medical and pharmacy claims and medical records review for patients (n = 200) who initiated sacubitril/valsartan between August 2015 and March 2016 preceding issuance of American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) focused update on new pharmacological therapy for HF (May 2016), which included recommendations for sacubitril/valsartan. A within-subject analysis compared symptoms and healthcare resource utilization before and after treatment initiation. Patients treated with sacubitril/valsartan had multiple comorbidities, and nearly all had previous treatment for HF. Most patients initiated sacubitril/valsartan at the lowest dose of 24/26 mg twice a day (BID), which remained unchanged during the observation period for half of the patients. During the first 6 weeks of treatment, few patients discontinued sacubitril/valsartan treatment (5.5%), and only 17% achieved the target dose of 97/103 mg BID after 4 months of t...Continue Reading

References

Jan 9, 2001·Journal of Clinical Epidemiology·C N KlabundeJ L Warren
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Jun 12, 2013·Journal of the American College of Cardiology·Clyde W YancyUNKNOWN American Heart Association Task Force on Practice Guidelines
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Dec 19, 2014·Circulation·Dariush MozaffarianUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Nov 26, 2015·The Nursing Clinics of North America·Chad Rogers, Nathania Bush
Feb 16, 2016·Pharmacoepidemiology and Drug Safety·Melissa L SantorelliKitaw Demissie
Feb 27, 2016·F1000Research·Takeshi Kitai, Wh Wilson Tang
Jul 16, 2016·Journal of the American College of Cardiology·Akshay S DesaiUNKNOWN PARADIGM-HF Investigators
Jan 27, 2017·Circulation·Emelia J BenjaminUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Dec 19, 2017·International Journal of Cardiology·Paola BeltránJulio Núñez

❮ Previous
Next ❯

Citations

Dec 13, 2018·Journal of Cardiovascular Pharmacology·Amy X DuJustin A Ezekowitz
Jul 11, 2019·Journal of Comparative Effectiveness Research·Herminio Morillas-ClimentAlfonso Valle-Muñoz
Nov 13, 2019·Journal of Cardiovascular Medicine·Seçkin DereliAhmet Kaya
Apr 4, 2020·Diabetes, Obesity & Metabolism·Javed ButlerJulio Rosenstock
May 30, 2020·British Journal of Clinical Pharmacology·Cormac KennedyMichael Barry
Jun 22, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Antonis S ManolisHelen Melita
Mar 2, 2019·Cardiovascular Drugs and Therapy·Carles Moliner-AbósEulàlia Roig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.